Pan-cancer mapping of single CD8 TÂ cell profiles reveals a TCF1:CXCR6 axis regulating CD28 co-stimulation and anti-tumor immunity.
Authors | |
Keywords | |
Abstract | CD8 T cells must persist and function in diverse tumor microenvironments to exert their effects. Thus, understanding common underlying expression programs could better inform the next generation of immunotherapies. We apply a generalizable matrix factorization algorithm that recovers both shared and context-specific expression programs from diverse datasets to a single-cell RNA sequencing (scRNA-seq) compendium of 33,161 CD8 T cells from 132 patients with seven human cancers. Our meta-single-cell analyses uncover a pan-cancer T cell dysfunction program that predicts clinical non-response to checkpoint blockade in melanoma and highlights CXCR6 as a pan-cancer marker of chronically activated T cells. Cxcr6 is trans-activated by AP-1 and repressed by TCF1. Using mouse models, we show that Cxcr6 deletion in CD8 T cells increases apoptosis of PD1TIM3 cells, dampens CD28 signaling, and compromises tumor growth control. Our study uncovers a TCF1:CXCR6 axis that counterbalances PD1-mediated suppression of CD8 cell responses and is essential for effective anti-tumor immunity. |
Year of Publication | 2024
|
Journal | Cell reports. Medicine
|
Pages | 101640
|
Date Published | 06/2024
|
ISSN | 2666-3791
|
DOI | 10.1016/j.xcrm.2024.101640
|
PubMed ID | 38959885
|
Links |